Navigation Links
Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007

JERSEY CITY, N.J.--(BUSINESS WIRE)--May 4, 2007 - Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company's next-generation calcineurin inhibitor, LX211, is the subject of two presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 6-10 in Fort Lauderdale, Florida.

The first, an oral presentation being given on May 5 during a satellite session of the American Uveitis Society by Quan Dong Nguyen, M.D. of the Wilmer Eye Institute, Johns Hopkins University and Hospitals, discusses the design of the ongoing LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) Phase 2/3 Clinical Trial Program. The three LUMINATE trials represent the first clinical development program aimed at supporting regulatory approval of a corticosteroid-sparing immunosuppressive agent in different types of sight-threatening, non-infectious uveitis.

The second, a poster presentation by Matthew A. Cunningham, senior medical student, senior author Robert Nussenblatt, MD, and collaborators from the National Eye Institute, Lux Biosciences, and Isotechnika, Inc., discusses preclinical data demonstrating the ability of subcutaneous injections of LX211 to prevent and reverse experimental autoimmune uveoretinitis (EAU) in rats. Cunningham commented, "We observed that in this animal model, LX211 could both prevent the onset of disease as well as reverse EAU at doses as low as 10 mg/kg. These preclinical results clearly support our view that LX211 may play an important future role in the treatment of uveitis."

The poster describes the induction of EAU in rats, which were then divided into three groups, designated preventative, therapeutic, and vehicle-control. Animals in the first two groups received daily subcutaneous injections of either cyclosporine A (CsA) at 40 mg/kg or LX211 at 2.5 mg/kg, 10 mg/kg or 40 mg/kg, with the preventative group beginning injections at day 0 and the therapeutic group beginning injections at day 7 after EAU induction. Six days after EAU induction, researchers began to evaluate the animals daily for clinical scores.

The vehicle-control and LX211 2.5 mg/kg therapeutic groups displayed the earliest clinical manifestations of EAU and highest clinical scores. None of the CsA or LX211 treated rats in the preventative group developed severe clinical disease. Histopathology confirmed that animals treated with LX211 at 40mg/kg were free of disease, in both therapeutic and preventative groups. These results were similar to results seen in the CsA group. LX211 therapeutic groups, 2.5 and 10 mg/kg, showed decreased histopathological EAU scores compared to controls. In rats treated with either LX211 or CsA, antigen-specific and non-specific responses of lymphocytes to the protein used to induce EAU were diminished compared to those of the control group.

"These positive preclinical results, combined with encouraging safety data from human clinical trials in other indications conducted by our partner Isotechnika, provide a strong rationale for our ongoing registration-directed LUMINATE studies of LX211 in uveitis," said Ulrich Grau, Ph.D., Lux Biosciences' president and chief executive officer. "We hope to complete enrollment in the LUMINATE trial program by early 2008 and, if successful, seek regulatory approval for LX211 in late 2008."

About LX211

LX211 is a next-generation calcineurin inhibitor to which Lux Biosciences has an exclusive worldwide license for ophthalmic indications from Isotechnika, Inc., of Edmonton, Canada (Isotechnika's code ISA247). Isotechnika is currently investigating ISA247 in phase 3 clinical trials in psoriasis patients, and in a phase 2b clinical trial in solid organ transplant recipients. The clinical data gathered to date indicate that LX211 is a potent calcin eurin inhibitor - a biological mechanism demonstrated to provide efficacy in a range of autoimmune diseases such as noninfectious uveitis - and also appears to be well tolerated. In addition to uveitis, Lux Biosciences plans to develop this molecule in other ophthalmic indications, including dry eye syndrome and age-related macular degeneration.

About Uveitis

Uveitis is an autoimmune disease characterized by chronic inflammation of the eye. There is substantial evidence implicating T-lymphocytes, key cells involved in inflammatory processes, in the development of the disease. Uveitis is an under-diagnosed and under-recognized medical condition that causes vision impairment, ocular pain, and loss of vision. Experts estimate that 10% of new U.S. cases of blindness result from this disease. Approximately 300,000 people suffer from uveitis in the United States alone, the majority of whom are affected by anterior uveitis. The only therapeutic class approved by the FDA for treatment of uveitis is corticosteroids, which are burdened with multiple side effects, such as hypertension, hyperglycemia, hypercholesterolemia, and in the eye, cataract formation and glaucoma.

About Lux Biosciences

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by:

-- A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux Biosciences will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments.

-- A clinical-stage portfolio of projects including: i) LX211, a next-generation calcineurin inhibitor that has potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities; and ii) LX201, a s ilicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007.

-- A proprietary product-enabling bio-erodible polymer technology that facilitates targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company's website at


Lux Biosciences, Inc.
Ulrich Grau, Ph.D., +1 201-946-0221
Kureczka/Martin Associates
Joan Kureczka, +1 415-821-2413 (Media)


Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... ... ... According to an article published November 6th by The Telegraph, ... British Columbia suggested that laws requiring bicyclists to wear helmets may not actually decrease ... reason for the controversial conclusion is that, while helmets have certainly prevented a great ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
Breaking Medicine News(10 mins):